SELECT
» Biotechnology facts and figures
» Drugs in development
» Key Technologies
DISEASES
» Anemia (2005)
» Breast Cancer (2007)
» Cardiovascular Diseases (2007)
» Diabetes (2005)
» Growth Hormone Deficiency (2005)
» Haemophilia (2005)
» Hepatitis B (2005)
» Inflammatory Bowel Disease (2007)
» Lymphomas (2005)
» Multiple Sclerosis (2005)
» Rheumatoid Arthritis and other Inflammatory Rheumatism (2007)
Biotechnology for
Lymphomas (2005)
<table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">The disease</span><br> <span class="rteColumn"> Cancer is a disease with a multitude of different forms. There are as many types of cancer as there are types of cells in our bodies. A cancer occurs in one cell, after a cascade of successive genetic events, starts to proliferate out of control and may eventually invade other organs and tissue. </span> <a href="more.php?diseaseid=22&bloc=1" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">How many people are affected ?</span><br> Approximately 10 million people are affected by cancer throughout the world. Europe has 2.8 million cases, and North America 1.4 million. <a href="more.php?diseaseid=22&bloc=2" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">How many people die from the disease?</span><br> With 5.243 deaths in France in 2000, of which 51% in men, lymphomas rank 7th in deaths from cancer and represent 3.5% of all deaths from cancer. In the United States in 2001, there were 7.9 deaths per 100.000 population per annum. <a href="more.php?diseaseid=22&bloc=3" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Living with the disease</span><br> Despite the real progress that has been made in detection and treatment, the mortality connected with cancer still remains significant. Cancer is the second cause of death in developed countries, i.e. almost 150,000 deaths per annum in France. Cancer is often a debilitating disease, both as a consequence of the disease itself and of the treatment. <a href="more.php?diseaseid=22&bloc=4" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> <tr> <td><span class="diseaseSubTitle">Treatment <font color='#FFFFFF' size=-2>Témoignage patient de </font> </span></td> </tr> <tr> <td><span class="diseaseText"><img src="../images/pix.gif" width="1" height="10"></span></td> </tr> </table> <table border="0" cellspacing="0" cellpadding="5"> <tr> <td valign="top" bgcolor="#B9E3FF"> <span class="diseaseSubTitle2">Traditional approach</span><br> There are three types of established treatment for cancer, some of which are complementary: surgery, which consists in removing all, or part, of the tumour, radiotherapy, and chemotherapy, which eliminate the cancer cells. The progress in chemotherapy has been significant and currently permits recovery from a certain number of cancers, but the products used lack specificity and also destroy healthy cells. Their use is therefore limited by high toxicity. <a href="more.php?diseaseid=22&bloc=5" class="lienBleu">More</a></td> <td> </td> <td valign="top" bgcolor="#B9E3FF"> <span class="diseaseSubTitle2">Biotech revolutions</span><br> The great breakthrough of biotechnology in the treatment of cancer has been the development of drugs specific to different types of cancer cells. With a better understanding of the mechanism behind cancerous cell-division specific "markers" of these cells have been identified. The development of monoclonal antibodies, in particular, has enabled the development of new treatment weapons in the fight against cancer. By definition, these " biodrugs" only attack their target cells, the cancer cells, and have very few side effects. <a href="more.php?diseaseid=22&bloc=6" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/spacer.gif" width="227" height="1"></td> <td><img src="../images/spacer.gif" width="1" height="1"></td> <td><img src="../images/spacer.gif" width="227" height="1"></td> </tr> <tr bgcolor="#B9E3FF"> <td colspan="3"> <span class="diseaseSubTitle2">Drugs currently available</span><br> Several of these monoclonal antibodies have been developed. Amongst them, rituximab (Mabthera®) which offers solutions in the treatment of certain lymphomas (a type of cancer of the blood), and trastuzumab (Herceptin®) which has a significant effect on 20 to 30% of breast cancers. <a href="more.php?diseaseid=22&bloc=7" class="lienBleu">More</a></td> </tr> <tr> <td colspan="3"><img src="../images/pix.gif" width="1" height="5"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Number of patients treated</span><br> In France, the target population for trastuzumab is approximately 10,000 patients per annum. For rituximab it is approximately 3,000 patients per annum. <a href="more.php?diseaseid=22&bloc=8" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Future</span><br> In the region of 400 new cancer drugs were being developed in 2003. Amongst these almost 200 were derived from the field of biotechnology, approximately 40 of which were monoclonal antibodies. <a href="more.php?diseaseid=22&bloc=9" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Costs to society</span><br> The use of these antibodies is economically interesting because, although they are more expensive to produce than traditional treatment, there are fewer side effects, and fewer days in hospital are required. Sales figures for anti-CD20 antibodies are significant. In 2003, they reached over € 1.5 billion. <a href="more.php?diseaseid=22&bloc=10" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table>
